欢迎访问《中国真菌学杂志》杂志官方网站,今天是 分享到:

中国真菌学杂志 2018, Vol. 13  Issue (6): 376-379.

综述 上一篇    下一篇

伊曲康唑临床应用的安全性分析

尚盼盼, 王爱平   

  1. 北京大学第一医院皮肤性病科 北京大学真菌和真菌病研究中心 皮肤病分子诊断北京市重点实验室, 北京 100034
  • 收稿日期:2018-04-24 出版日期:2018-12-28 发布日期:2018-12-28
  • 通讯作者: 王爱平,E-mail:wangap516@163.com E-mail:wangap516@163.com
  • 作者简介:尚盼盼,男(汉族),硕士,住院医师.E-mail:shangpanpan-03@163.com

Safety analysis of itraconazole clinical application

SHANG Pan-pan, WANG Ai-ping   

  1. Department of Dermatology and Venereology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, and Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, Beijing 100034, China
  • Received:2018-04-24 Online:2018-12-28 Published:2018-12-28

摘要:

伊曲康唑作为第一代三唑类抗真菌药物,上市近30年,由于其广谱的抗真菌谱,被广泛应用于临床治疗浅部及深部真菌感染,少部分患者在应用伊曲康唑后会出现胃肠道反应、肝酶升高等不良反应,本文就伊曲康唑临床应用的不良反应及在儿童、老年人和孕妇等特殊人群中应用的安全性进行综述分析。

关键词: 伊曲康唑, 安全性, 治疗

Abstract:

Itraconazole, as the first generation triazole antifungal drugs, has been commoditized for nearly 30 years. As it's broad-spectrum of antifungal, itraconazole has been widely used in the treatment of fungal infections. Small patients with itraconazole may experience adverse reactions such as gastrointestinal reactions and elevated liver enzymes. This article reviews the safety of clinical application of itraconazole in different populations.

Key words: itraconazole, safety, treatment

中图分类号: